[
    [
        {
            "time": "2020-08-02",
            "original_text": "上周电子和医药行业涨幅领先——华泰金工FOF投资周报20200802",
            "features": {
                "keywords": [
                    "电子",
                    "医药",
                    "涨幅",
                    "华泰金工",
                    "FOF投资"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "电子",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上周电子和医药行业涨幅领先——华泰金工FOF投资周报20200802",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "誉衡药业转型艰难",
            "features": {
                "keywords": [
                    "誉衡药业",
                    "转型",
                    "艰难"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "誉衡药业转型艰难",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "信迪利二季度5亿 上半年销售接近O药全年",
            "features": {
                "keywords": [
                    "信迪利",
                    "二季度",
                    "销售",
                    "O药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "信迪利二季度5亿 上半年销售接近O药全年",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药营收、净利增速下滑 股权激励计划能否奏效？ 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收",
                    "净利",
                    "增速下滑",
                    "股权激励",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药营收、净利增速下滑 股权激励计划能否奏效？ 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药净赚26亿背后:疫情下仍花35亿开会, 行贿丑闻致子公司清算 其他违规处罚",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "净赚26亿",
                    "疫情",
                    "开会",
                    "行贿丑闻",
                    "子公司清算",
                    "违规处罚"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药净赚26亿背后:疫情下仍花35亿开会, 行贿丑闻致子公司清算 其他违规处罚",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药(600276)：中报业绩稳定增长 股权激励保障长期动力",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "中报业绩",
                    "稳定增长",
                    "股权激励",
                    "长期动力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276)：中报业绩稳定增长 股权激励保障长期动力",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业每周医览药闻：疫苗依然是解决新冠疫情的最根本方法",
            "features": {
                "keywords": [
                    "医药行业",
                    "疫苗",
                    "新冠疫情",
                    "根本方法"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业每周医览药闻：疫苗依然是解决新冠疫情的最根本方法",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]